Evolus (EOLS) Projected to Post Quarterly Earnings on Tuesday

Evolus (NASDAQ:EOLS) is projected to issue its Q4 2025 results after the market closes on Tuesday, March 3rd. Analysts expect Evolus to post earnings of $0.09 per share and revenue of $89.5810 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Tuesday, March 3, 2026 at 4:30 PM ET.

Evolus Trading Down 4.2%

Shares of EOLS stock opened at $4.30 on Friday. The stock has a market cap of $278.73 million, a P/E ratio of -4.67 and a beta of 1.11. Evolus has a 1 year low of $4.09 and a 1 year high of $14.94. The stock has a 50 day simple moving average of $5.22 and a 200 day simple moving average of $6.28.

Analyst Ratings Changes

A number of research firms have recently weighed in on EOLS. HC Wainwright cut their target price on Evolus from $20.00 to $13.00 and set a “buy” rating for the company in a research report on Tuesday, February 3rd. Stifel Nicolaus dropped their price target on Evolus from $20.00 to $17.00 and set a “buy” rating for the company in a research note on Tuesday, January 13th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Evolus in a research note on Monday, December 22nd. Needham & Company LLC reissued a “hold” rating on shares of Evolus in a report on Wednesday, December 24th. Finally, Wall Street Zen upgraded shares of Evolus from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Five analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Evolus currently has a consensus rating of “Moderate Buy” and an average target price of $17.50.

Insider Transactions at Evolus

In other Evolus news, insider David Moatazedi sold 10,539 shares of Evolus stock in a transaction dated Monday, December 22nd. The stock was sold at an average price of $7.15, for a total value of $75,353.85. Following the transaction, the insider owned 354,388 shares in the company, valued at $2,533,874.20. The trade was a 2.89% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 5.90% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Evolus

A number of hedge funds have recently made changes to their positions in the stock. Man Group plc lifted its stake in Evolus by 23.5% in the 2nd quarter. Man Group plc now owns 125,749 shares of the company’s stock valued at $1,158,000 after purchasing an additional 23,922 shares during the last quarter. Soleus Capital Management L.P. grew its stake in shares of Evolus by 96.4% during the second quarter. Soleus Capital Management L.P. now owns 2,119,000 shares of the company’s stock worth $19,516,000 after buying an additional 1,039,842 shares during the last quarter. Tower Research Capital LLC TRC increased its holdings in shares of Evolus by 340.2% during the second quarter. Tower Research Capital LLC TRC now owns 7,364 shares of the company’s stock worth $68,000 after buying an additional 5,691 shares in the last quarter. Caxton Associates LLP bought a new position in shares of Evolus in the 2nd quarter valued at $148,000. Finally, Vanguard Group Inc. lifted its stake in shares of Evolus by 3.3% in the 3rd quarter. Vanguard Group Inc. now owns 3,428,943 shares of the company’s stock valued at $21,054,000 after acquiring an additional 110,693 shares during the last quarter. 90.69% of the stock is currently owned by institutional investors and hedge funds.

About Evolus

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.